Literature DB >> 12867492

Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.

Stefan Wilkening1, Frank Stahl, Augustinus Bader.   

Abstract

Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies. In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens. Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture. All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected. We supposed that the lack of specific enzymes accounts for their inability to process these promutagens. Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction. The genes code for cytochromes p450 and, in addition, for a series of important phase II enzymes. The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples. On the other hand, expression levels in HepG2 differed significantly from that in human. Activity and expression, especially of phase I enzymes, were demonstrated to be extremely low in HepG2 cells. Up-regulation of specific genes by test substances was similar in both cell types. In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12867492     DOI: 10.1124/dmd.31.8.1035

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  166 in total

1.  Quantitative real-time polymerase chain reaction: methodical analysis and mathematical model.

Authors:  Stefan Wilkening; Augustinus Bader
Journal:  J Biomol Tech       Date:  2004-06

Review 2.  Human induced pluripotent stem cells--from mechanisms to clinical applications.

Authors:  Katharina Drews; Justyna Jozefczuk; Alessandro Prigione; James Adjaye
Journal:  J Mol Med (Berl)       Date:  2012-05-30       Impact factor: 4.599

3.  In situ patterned micro 3D liver constructs for parallel toxicology testing in a fluidic device.

Authors:  Aleksander Skardal; Mahesh Devarasetty; Shay Soker; Adam R Hall
Journal:  Biofabrication       Date:  2015-09-10       Impact factor: 9.954

Review 4.  Organ-on-a-chip for assessing environmental toxicants.

Authors:  Soohee Cho; Jeong-Yeol Yoon
Journal:  Curr Opin Biotechnol       Date:  2017-01-11       Impact factor: 9.740

5.  Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes.

Authors:  A C S Fabre; P Vantourout; E Champagne; F Tercé; C Rolland; B Perret; X Collet; R Barbaras; L O Martinez
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

Review 6.  Thinking outside the liver: induced pluripotent stem cells for hepatic applications.

Authors:  Mekala Subba Rao; Mitnala Sasikala; D Nageshwar Reddy
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

7.  Similarities and differences between two modes of antagonism of the thyroid hormone receptor.

Authors:  Prabodh Sadana; Jong Yeon Hwang; Ramy R Attia; Leggy A Arnold; Geoffrey Neale; R Kiplin Guy
Journal:  ACS Chem Biol       Date:  2011-08-15       Impact factor: 5.100

8.  Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors.

Authors:  Joanna Fraczek; Sarah Deleu; Aneta Lukaszuk; Tatyana Doktorova; Dirk Tourwé; Albert Geerts; Tamara Vanhaecke; Karin Vanderkerken; Vera Rogiers
Journal:  Invest New Drugs       Date:  2008-09-30       Impact factor: 3.850

Review 9.  Organ-on-a-chip platforms for studying drug delivery systems.

Authors:  Nupura S Bhise; João Ribas; Vijayan Manoharan; Yu Shrike Zhang; Alessandro Polini; Solange Massa; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

10.  Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.

Authors:  Alison E Aitken; Choon-Myung Lee; Edward T Morgan
Journal:  Free Radic Biol Med       Date:  2007-12-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.